Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution (RESISTANCE)

11. mai 2026 oppdatert av: Centre Hospitalier Universitaire de Nice

Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution: a Pilot Study - RESISTANCE

Worldwide, cerebrovascular accidents (also known as strokes) are the leading cause of acquired disability, the second-leading cause of dementia (after Alzheimer's disease) and the second-leading cause of death (but the leading cause of death among women). A mechanical thrombectomy (MT) allows the recanalization of the occluded cerebral artery during an acute ischemic stroke, by removing the blood clot with a mechanical device inserted endovascularly under image guidance. MTs are the optimal treatment for a large number of patients presenting an occlusion in an anterior artery (the internal carotid artery and the proximal segment of the middle cerebral artery). Reperfusion is considered satisfactory if the mTICI score at the end of the procedure is of mTICI 2c or mTICI 3. Despite these scores having been obtained by 71% of patients during the randomized trials, showing the superiority of MT over intravenous thrombolysis, only 27% of these patients were free of neurological deficits at 3 months . Therefore, there is a discrepancy between the high rate of macroscopic recanalization and clinical results. One hypothesis to explain this discrepancy is that despite high quality macroscopic recanalization, reperfusion of the cerebral microcirculation remains insufficient: macroscopic recanalization is not equivalent to microscopic reperfusion. This discrepancy also exists in cardiology: despite a high rate of coronary artery recanalization when patients with an ST- segment elevation myocardial infarction are in emergency care, half of these patients later exhibit coronary microvascular dysfunction. The absence of reperfusion is associated with an increased risk of cardiovascular death, recurring myocardial infarctions, cardiogenic shock and heart failure one year after the coronary recanalization for an ST-segment elevation myocardial infarction. It has been shown that continuous intracoronary thermodilution can be used to quantify coronary blood flow and the absolute value of microcirculatory resistance (in Wood units). There are not currently any tools that can quantify cerebral microcirculation immediately after an MT.

The aim of this study is to evaluate the feasibility and safety of using a pressure/temperature sensing guidewire to measure cerebral microcirculatory resistance using thermodilution in patients with a score of mTICI 2c or 3 after MT for the management of acute ischemic stroke in the anterior circulation.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

15

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alpes-maritimes
      • Nice, Alpes-maritimes, Frankrike, 06000
        • Rekruttering
        • Chu De Nice
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Men or women aged 18 to 80
  • Social Security beneficiaries
  • Obtained signed consent to participate in the study
  • TICI 2c or TICI 3 score after mechanical thrombectomy
  • Patients hospitalized for ischemic stroke due to middle cerebral artery thrombosis

Exclusion Criteria:

  • Spasm of an artery without significant stenosis
  • Vessel diameter less than 1 mm
  • Severe visceral failure
  • Local infection
  • Minors
  • Adults protected by law
  • Patients deprived of their liberty
  • Subjects who are uncooperative or unable to meet the requirements of the protocol
  • Subjects participating in another clinical trial or in a period of exclusion from a previous clinical trial
  • Pregnant women

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: fully recanalization

The measurements will be taken as follows: once satisfactory recanalization has been achieved (mTICI 2c or 3), the suction catheter will be placed at the origin of the M1 segment. Through this catheter, the pressure/temperature measurement microguide will be placed at the distal part of M1. The microcatheter will be placed on the microguide, with its tip positioned at the outlet of the aspiration catheter.

A pressure sensor will be connected to the aspiration catheter. The microcatheter will be connected to the saline injector programmed to inject saline. The microguide is replaced in the microcatheter 165 seconds after the start of the injection. The trace of the variation in parameters will be recorded on the Coroventis station. A control injection will be performed after removal of the microcatheter and microguide from the suction catheter to ensure that there are no complications due to the measurement.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The primary objective is to assess the feasibility of measuring cerebral blood flow and cerebral microcirculatory resistance using thermodilution with the rayflow microcatheter and pressurewire guide.
Tidsramme: Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
The primary evaluation criterion is the proportion of patients for whom measurements of cerebral blood flow and cerebral microcirculatory resistance using thermodilution were possible.
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To assess the safety of using thermodilution to measure cerebral blood flow and cerebral microcirculatory resistance
Tidsramme: Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
The safety of the procedure will be evaluated by counting the number of deaths, perforations and dissections associated with the use of the guidewire and/or the microcatheter and/or the injection of physiological serum.
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
To describe the clinical evolution of patients
Tidsramme: DAY 90
Complications will be reported according to the recommendations of the Cardiovascular and Interventional Radiological Society of Europe
DAY 90
Determine the threshold value of the cerebral microcirculation resistance index that allows the definition of an optimal sensitivity/specificity pair for the prognosis of neurological progression (favorable or not).
Tidsramme: day 90
The value of the cerebral microcirculation resistance index for distinguishing between patients who will have a favorable neurological outcome (mRS ≤ 2) and those who will have an unfavorable outcome (mRS > 2) will be calculated from the ROC curve generated by the data collected.
day 90
Measure the additional radiation dose received by patient
Tidsramme: day 1
The increase in the additional dose will be compared to that corresponding to the patient's usual treatment.
day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. april 2026

Primær fullføring (Antatt)

1. mai 2027

Studiet fullført (Antatt)

1. november 2027

Datoer for studieregistrering

Først innsendt

6. februar 2026

Først innsendt som oppfylte QC-kriteriene

27. april 2026

Først lagt ut (Faktiske)

5. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere